RNS & Investor News

2021

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2020

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2019

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2018

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2017

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2016

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2015

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2014

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM


2013

PDMR Dealing

01 September 2021

Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.

Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

René Kamminga

2

Reason for notification

 

a.

Position/Status

PDMR

b.

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

8,188 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 8,188 ordinary shares in the Company

 

c.

Price(s) and volume(s)

     
 

Price(s) per share

Volume(s)

 

55.4p

8,188

 
 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

31 August 2021

f.

Place of the transaction

London Stock Exchange, AIM